Navigation Links
CutisPharma Announces Issuance of a Patent for Suppository Compounding
Date:11/6/2008

US patent for the preparation, storage, and dispensing of compounded suppositories

WOBURN, Mass., Nov. 6 /PRNewswire/ -- CutisPharma, Inc. today announced that it has received approval from the United States Patent and Trademark Office for its patent (US 7,434,690) regarding a container and kit for the preparation, storage and dispensing of compounded suppositories.

"By its very nature, the process of compounding suppositories is cumbersome, time-consuming and in general, without adequate compensation" said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "Our container (suppository mold) and the method for suppository-compounding is user-friendly and time saving for a pharmacy. Our suppository mold is also customer friendly because the take-home molds are especially designed to not only maintain the integrity of each suppository once compounded, but also provide convenient dispensing tools", he added.

Currently CutisPharma has FIRST(R) Progesterone Vaginal Suppository Unit-of-Use Prescription Compounding Kit product line available, which uses the patented container. The line includes FIRST(R) - Progesterone VGS 25, 50, 100, 200 and 400 representing various strengths (mg.). The kits are made for a single patient and include pre-weighed progesterone, and suppository base, and the patented disposable container/mold for preparation, storage, and dispensing of the suppositories. A single NDC number assigned for the entire kit aids the third party reimbursement process, reduces audit- related adjustments, and the use of these FIRST(R) kits facilitates compliance with USP Chapter <795>. This patented container, kit, and the method will also be used for future suppository compounding kits such as Boric Acid, Morphine, and others.

CutisPharma estimates that over 1.5 million progesterone suppository prescriptions are written in the U.S. annually, representing a potential of nearly $100 million at the retail level. The Kit allows a pharmacy an easy entry into this market. The Company is experiencing a steady conversion from the conventional way to the FIRST(R) - way.

FIRST(R) products save dispensing time, are easy to use, and can be compounded by the pharmacist while the patient waits increasing customer satisfaction. Using FIRST(R) VGS kits, the pharmacist can compound a prescription for 30 vaginal suppositories 4 to 5 times faster than those prepared by the traditional method using a metal suppository mold or polystyrene shells.

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(R) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at http://www.cutispharma.com/


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
2. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
3. Stereotaxis Announces New Management Appointment
4. SXC Health Solutions announces third quarter financial results
5. 360 Healthcare Staffing Announces Agreement With BlueSky Medical Staffing Software
6. Cardinal Health Announces Preliminary Shareholder Voting Results at Annual Meeting
7. Dialysis Corporation of America Announces $25 Million Credit Facility
8. Cornerstone Therapeutics Announces New Board of Directors
9. CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results
10. BD Announces Executive Appointments of President and Chief Financial Officer
11. BD Announces Results for Fourth Fiscal Quarter and Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... “Life Under Blankets”: an entrancing story about one ... Under Blankets” is the creation of published author, Kimberly Mitchell, who earned her bachelor’s ... went on to pursue a master’s degree in education in the field of curriculum ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Valentine’s Day is a time when many people ... ones. For those who may be looking for the ideal present, Atlanta-based Perimeter Plastic ... get an additional $25 free. Or, spend $200 and get $50 free. , “A ...
(Date:1/22/2017)... FL (PRWEB) , ... January 22, 2017 , ... Zifam ... customers across the world, recently met with big-name retail buyers at the January ECRM ... evidence of efficacy and uses the utmost safety standards in all of its creations ...
(Date:1/22/2017)... TX (PRWEB) , ... January 22, 2017 , ... ... provide slow results. Often the results of a simple test will take days to ... Any Lab Test Now offers customers direct access to their lab tests, bypassing the ...
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Germany, announced it is bringing its product to the United States as part of ... over the last 25 years, Alcovit aims to reduce the productions of nasty toxins ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 A new Transparency Market Research report ... valued at US$0.53 bn in 2013 and is predicted to touch ... between 2014 and 2022. The title of the report is "Non-invasive ... Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), also referred to ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
(Date:1/23/2017)... Jan 23, 2017 NeuroVive Pharmaceutical AB ... signed a preclinical collaboration agreement with the Children,s Hospital of ... Falk , M.D., a US key opinion leader in the ... ... evaluate compounds from NeuroVive,s research program, NVP015, in certain experimental ...
Breaking Medicine Technology: